

[shalviri\\_g@yahoo.com](mailto:shalviri_g@yahoo.com)

Bayesian Confidence Propagation Neural Network (BCPNN) :

Proportional Reporting Ratio (PRR) Reporting Odds Ratio(ROR)

$\geq \geq , \geq$

BCPNN

PRR

ROR

BCPNN

Proportional (PRRs) ,  
Bayesian data mining Reporting Ratios

.()

.()

Prescription Event ) PEM  
(Monitoring  
[Uppsala Monitoring Center  
(UMC )  
WHO

.()

Bayesian  
Bayesian Confidence ) BCPNN  
(Propagation Neural Network  
.()

.()

Medicines )  
(Control Agency or MCA

ADR

.()

(PRRs)  
Proportional Reporting Ratios  
Evans .  
.()

odds ratios

PRR

487

( % )

( % )

( % )

(crude)

( % )

( % )

FDA

Empirical ) EBS

( )

Data mining  
( Bayesian Screening

Proportional Reporting Ratios

Neural Network Reporting Odds Ratios

Bayesian

( )

Slone Epidemiology Unit or ) Slone

( SEU

(.)

PRR

Excel

PRR ≥ ( )

Chi-squared

PRR % (

(WHO Adverse Drug Reaction Terminology)

( )

Reporting Odds (ROR)

( Preferred Term)

Ratio

ROR ( )

%

ROR

ROR

%

Access

Query

\_\_\_\_\_

\_\_\_\_\_

b

a

d

c

\_\_\_\_\_

Bayesian Confidence

Propagation Neural Network ( BCPNN)

Proportional Reporting Ratio (PRR)

Reporting Odds Ratio (ROR)

Bayesian Confidence Propagation Neural Network (BCPNN)

Information ) IC ( )

(Component

(

)

%

IC

PRR

IC-2SD

chi – squared

IC-2SD



( / %)

% /

) ROR

(% / ) (

(% / )

cut-off

(% , )

) IC

(% , ) (

SNIP

(% / )

( )  
(Strength)

(NEW)

IVIG

)  
(Clinical Importance) (

( Potentially preventable)

(SNIP)

PRR

%

%

( )

% / % / BCPNN , ROR , PRR

EBS BCPNN PRRS

% /

IC-2SD

Archive of SID

PRR

( proportional mortality ratios )

PRR

BCPNN

PRRs

FDA

EBS

WHO

(

UK Medicines Control Agency MCA)

PRR

( % )

chi- PRR

association

squared

BCPNN IC

/

UK yellow card system

/

PRRs

( )

MCA

Important New Strong) SNIP

( Preventable

IVIG

BCPNN

WHO

BCPNN

WHO

BCPNN

( )

PRRs

BCPNN EBS

NSAIDs

( RORs PRRs )

Archive of SID



Archive of SID

---

---

% ,	% ,	PRR $\geq$ 2, $\chi^2 \geq 4$	$\geq$
% ,	% ,	ROR, CI>1	
% ,	% ,	PRR, CI>1	
% ,	% ,	IC, IC-2SD>0	

% ,	% ,	PRR $\geq$ 2, $\chi^2 \geq 4$	$\geq$
		ROR, CI>1	
% ,	% ,	PRR, CI>1	
		IC, IC-2SD>0	
% ,	% ,		
% ,	% ,		
% ,	% ,	PRR $\geq$ 2, $\chi^2 \geq 4$	$\geq$
		ROR, CI>1	
% ,	% ,	PRR, CI>1	
		IC, IC-2SD>0	

## References

1- World Health organization. The importance of pharmacovigilance, safety monitoring of medicinal products. WHO: Geneva, 2002.

2- Mann R.D, Andrews E.B, Pharmacovigilance. John Wiley & Sons Ltd. 2002.

3- Boxtel J.V, Santoso B., Edwards I.R. Drug benefits and Risks, International textbook of clinical pharmacology. John Wiley & Sons Ltd. 2001.

4- Meyboom, R.H.B. Detecting Adverse Drug reactions, Pharmacovigilance in the Netherlands. The Netherlands pharmacovigilance Foundation LAREB.1998.

5- Meyboom, R.H.B., Egberts, A.C.G. Edwards, I.R. Principles of Signal

- Detection in Pharmacovigilance. Drug Safety 1997; 16 (6): 355-365.
- 6- Hauben, M. Zhout, X. Quantitative methods in pharmacovigilance, focus on signal detection. Drug Safety 2003; 26(3): 159-186.
- 7- Bate, A. Lindquist, M. Edwards, I.R. Orre, R. A data mining approach for signal detection and analysis. Drug Safety 2002; 25(6): 393-397.
- 8- Evans, S. J. W. Waller, P. C. Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug safety 2001; 10: 483-486.
- 9- Szarfman, A. Machado, S.G. O'Neill, R.T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Safety 2002; 25(6): 381-392.
- 10- Gould, A.L. Practical pharmacovigilance analysis strategies. Pharmacoepidemiology and drug safety 2003; 12: 559-574.
- 11- WHO adverse reaction terminology. the Uppsala Monitoring Center, 2003.
- 12- WHO Collaborating Center for International Drug Monitoring, Viewpoint, watching for safer medicines. Part 2. the Uppsala Monitoring Center, 2004; 56.
- 13- Waller, P.C. Lee, E.H. Responding to drug safety issues. Pharmacoepidemiology and drug safety. 1999; 8: 535-552.
- 14- Puijtenbroek, E.P. Grootheest, K. Diemont, W.L. Leufkens, H.G. M. Egberts, A.C.G. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol, 2001, 52, 579-586.
- 15- Stahl, M. Lindquist, M. Edwards I. R. Brown, E.G. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiology and drug safety 2004; 13: 355-363.
- 16- Puijtenbroek, E.P. Bate, A. Leufkens, HGM. Lindquist, M. Orre, R. Egberts, ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and drug safety 2002; 11: 3-10.